deferasirox has been researched along with Anemia, Hypoplastic in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (10.00) | 29.6817 |
| 2010's | 16 (80.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, B; Zhang, R | 1 |
| Andreani, G; Cilloni, D; De Gobbi, M; Dragani, M; Saglio, G | 1 |
| Hu, H; Liu, W; Wen, X; Wu, D; Ye, B; Zhou, Y | 1 |
| Chang, CS; Chang, MC; Chang, TK; Chen, TY; Chen, YC; Chiou, TJ; Hwang, WS; Ko, BS; Lin, SF; Lu, YC; Yeh, SP | 1 |
| El-Ali, A; Ganser, A; Habr, D; Hsu, HC; Lee, JW; Martin, N; Porter, JB; Shen, ZX; Yoon, SS | 1 |
| Chung, J; Jang, JH; Jo, DY; Kim, HJ; Lee, JH; Lee, JW; Yoon, SS | 1 |
| Abe, T; Fujii, S; Fujita, M; Iyama, S; Jomen, W; Kato, J; Kobune, M; Kuroda, H; Maeda, M; Matsuno, T; Miyanishi, K; Nagashima, K; Sakurai, T; Sato, M; Yamada, M | 1 |
| Cheong, JW; Chung, J; Hyun, MS; Jo, DY; Joo, YD; Jung, CW; Kim, BS; Kim, CS; Kim, HJ; Kim, HY; Lee, JH; Lee, KH; Min, YH; Park, CY; Park, HS; Seong, CM; Shim, H; Sohn, SK; Yoon, HJ; Yoon, SS | 1 |
| Banerjee, A; Bentley, M; Bird, R; Forsyth, C; Grigg, A; Grigoriadis, G; Kellner, S; Mifsud, NA; Motum, P; Opat, S; Szer, J; Tam, C | 1 |
| Bae, SH; Chung, JS; Hyun, MS; Joo, YD; Kim, H; Kim, HG; Kim, IH; Kim, SH; Kim, YS; Kwon, KY; Lee, GW; Lee, HS; Lee, SM; Lee, WS; Lim, SN; Moon, JH; Park, KT; Ryoo, HM; Sohn, SK | 1 |
| Agaoglu, L; Glaser, S; Kilinç, Y; Kohgo, Y; Lim, LC; Miyamura, K; Urabe, A; Wang, C; Warzocha, K; Wiktor-Jedrzejczak, W | 1 |
| Chang, H; Hu, D; Hu, L; Huang, J; Liu, F; Nie, N; Quan, R; Shao, Y; Shi, J; Tang, X; Xiao, H; Zhang, F; Zhang, J; Zhang, L; Zheng, C; Zheng, Y; Zhou, Y | 1 |
| Hata, T; Ishikawa, T; Kato, J; Kondo, M; Miyazawa, K; Mori, H; Nakao, S; Ohyashiki, K; Omine, M; Ozawa, K; Rojkjaer, L; Taniguchi, J; Tanii, H; Tatsumi, Y; Urabe, A | 1 |
| Ito, Y; Kiguchi, T; Kimura, Y; Ohyashiki, K | 1 |
| Alati, C; Marino, A; Nobile, F; Oliva, EN; Praticò, G; Ronco, F | 1 |
| Domokos, G; Ganser, A; Habr, D; Hsu, HC; Lee, JW; Porter, JB; Roubert, B; Shen, ZX; Yoon, SS | 1 |
| Im, HJ; Kim, BE; Koh, KN; Park, M; Seo, JJ | 1 |
| Melpignano, A; Quarta, A; Quarta, G | 1 |
| Cho, B; Chung, NG; Jang, PS; Jeong, DC; Kim, HK; Lee, JW | 1 |
| Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Yahng, SA | 1 |
1 review(s) available for deferasirox and Anemia, Hypoplastic
| Article | Year |
|---|---|
Synergistic effect of eltrombopag and deferasirox in aplastic anemia: a clinical case and review of the literature.
Topics: Anemia, Aplastic; Benzoates; Deferasirox; Humans; Hydrazines; Pyrazoles | 2020 |
7 trial(s) available for deferasirox and Anemia, Hypoplastic
| Article | Year |
|---|---|
Long-term safety and efficacy of deferasirox in patients with myelodysplastic syndrome, aplastic anemia and other rare anemia in Taiwan.
Topics: Aged; Aged, 80 and over; Anemia, Aplastic; Deferasirox; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Skin Diseases; Taiwan | 2019 |
Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study.
Topics: Adolescent; Adult; Anemia, Aplastic; Benzoates; Blood Platelets; Child; Deferasirox; Female; Ferritins; Hemoglobins; Humans; Immunosuppressive Agents; Iron Chelating Agents; Male; Middle Aged; Neutrophils; Prospective Studies; Treatment Outcome; Triazoles; Young Adult | 2013 |
Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.
Topics: Adult; Aged; Anemia, Aplastic; Benzoates; Deferasirox; Female; Ferritins; Humans; Iron; Iron Overload; Liver; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Transfusion Reaction; Triazoles | 2014 |
Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Benzoates; Deferasirox; Erythrocyte Transfusion; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Triazoles | 2015 |
Deferasirox Decreases Liver Iron Concentration in Iron-Overloaded Patients with Myelodysplastic Syndromes, Aplastic Anemia and Other Rare Anemias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Benzoates; Child; Child, Preschool; Deferasirox; Humans; Iron Overload; Liver; Middle Aged; Myelodysplastic Syndromes; Triazoles | 2015 |
A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Asian People; Benzoates; Blood Transfusion; Deferasirox; Dose-Response Relationship, Drug; Female; Humans; Iron Chelating Agents; Iron Overload; Japan; Male; Middle Aged; Myelodysplastic Syndromes; Triazoles | 2008 |
Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial.
Topics: Adolescent; Adult; Anemia, Aplastic; Benzoates; Chelation Therapy; Creatinine; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Male; Middle Aged; Prospective Studies; Triazoles; Young Adult | 2010 |
12 other study(ies) available for deferasirox and Anemia, Hypoplastic
| Article | Year |
|---|---|
Dose of deferasirox correlates with its effects, which differ between low-risk myelodysplastic syndrome and aplastic anaemia.
Topics: Anemia, Aplastic; Benzoates; Creatinine; Deferasirox; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Triazoles | 2022 |
Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload.
Topics: Anemia, Aplastic; Animals; Benzoates; Deferasirox; Deferoxamine; Disease Models, Animal; Drug Therapy, Combination; Female; Iron Chelating Agents; Iron Overload; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Triazoles | 2018 |
Korean guideline for iron chelation therapy in transfusion-induced iron overload.
Topics: Anemia, Aplastic; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Republic of Korea; Transfusion Reaction; Triazoles | 2013 |
[Hematologic improvement with deferasirox following tandem antithymocyte globulin treatment in a transfusion-dependent patient with severe aplastic anemia].
Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Blood Transfusion; Cyclosporine; Deferasirox; Humans; Iron Chelating Agents; Male; Middle Aged; Transfusion Reaction; Treatment Outcome; Triazoles | 2013 |
The oral iron chelator deferasirox inhibits NF-κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia.
Topics: Anemia, Aplastic; Animals; Benzoates; Bone Marrow Cells; Cell Line; Cells, Cultured; Deferasirox; Deferoxamine; Gene Expression Regulation, Neoplastic; Humans; Iron Chelating Agents; Macrophages; Male; Mice; Myelodysplastic Syndromes; NF-kappa B; RNA, Long Noncoding; Transcription, Genetic; Triazoles; Tumor Necrosis Factor-alpha | 2015 |
[Efficacy and safety of deferasirox in aplastic anemia patients with iron overload: a single arm, multi-center,prospective study in China].
Topics: Anemia, Aplastic; Benzoates; Blood Transfusion; China; Deferasirox; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Prospective Studies; Triazoles | 2016 |
Restoration of cardiac function by an iron chelator, deferasirox, in a patient with aplastic anemia and cardiac iron overload.
Topics: Anemia, Aplastic; Benzoates; Deferasirox; Female; Heart; Humans; Iron Chelating Agents; Magnetic Resonance Imaging; Triazoles; Young Adult | 2009 |
Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients.
Topics: Anemia, Aplastic; Benzoates; Blood Transfusion; Deferasirox; Female; Hematopoiesis; Humans; Iron Chelating Agents; Male; Middle Aged; Myelodysplastic Syndromes; Triazoles | 2010 |
Restoration of hematopoiesis after iron chelation therapy with deferasirox in 2 children with severe aplastic anemia.
Topics: Anemia, Aplastic; Benzoates; Child; Deferasirox; Hematopoiesis; Humans; Iron Chelating Agents; Iron Overload; Male; Severity of Illness Index; Transfusion Reaction; Triazoles | 2010 |
Oral iron chelator deferasirox in the treatment of secondary hemochromatosis following bone marrow transplantation in a patient with severe aplastic anemia.
Topics: Adult; Anemia, Aplastic; Benzoates; Bone Marrow Transplantation; Deferasirox; Ferritins; Hemochromatosis; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Triazoles | 2011 |
Iron chelation therapy with deferasirox results in recovery of hematopoiesis in a child with aplastic anemia.
Topics: Anemia, Aplastic; Benzoates; Child, Preschool; Deferasirox; Hematopoiesis; Humans; Iron Chelating Agents; Male; Treatment Outcome; Triazoles | 2011 |
Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.
Topics: Adult; Anemia, Aplastic; Benzoates; Chelation Therapy; Deferasirox; Erythrocyte Transfusion; Female; Ferritins; Hematopoiesis; Humans; Immunosuppressive Agents; Iron; Iron Chelating Agents; Iron Overload; Male; Platelet Transfusion; Transfusion Reaction; Triazoles | 2013 |